A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

BACKGROUND: Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer. METHODS: This was a prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jin, Huang, Jiahui, Shen, Lili, Zhu, Siji, Gao, Weiqi, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364473/
https://www.ncbi.nlm.nih.gov/pubmed/32677982
http://dx.doi.org/10.1186/s12885-020-07156-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364473/
https://www.ncbi.nlm.nih.gov/pubmed/32677982
http://dx.doi.org/10.1186/s12885-020-07156-x

Ejemplares similares